Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Background Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age. Atopic dermatitis is characterised by dry, inflamed skin accompanied by...

Full description

Bibliographic Details
Main Authors: Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann
Format: Article
Language:English
Published: NIHR Journals Library 2024-01-01
Series:Health Technology Assessment
Subjects:
atopic dermatitis
abrocitinibatopic dermatitis
tralokinumab
upadacitinib
cost effectivenesssystematic review
cost effectivenesstralokinumab
Online Access:https://doi.org/10.3310/LEXB9006

Internet

https://doi.org/10.3310/LEXB9006

Similar Items